Clene misses in ALS trial

 

• The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeks
  

• Prespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks

• Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trial

• Clene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and others

• Clene is pursuing multiple paths, including ongoing discussions with potential strategic partners, in its goal of marketing authorization

• Clene to host investor call and webcast at 8:30 am EDT today

Clene will host a conference call and webcast at 8:30 am EDT to discuss the Healey ALS Platform trial topline results for CNM-Au8. Members of Clene’s executive team will lead the discussion.

Time and Date: 8:30 a.m. EDT on Oct. 3, 2022
Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)
Conference ID: 5318408
Press *1 to ask or withdraw a question, or *0 for operator assistance.

To access the live webcast, please register online at this link. Participants are requested to register at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months. A live audio webcast of the call will be available on the Investors section of the Company’s website Events page. An archived webcast will be available on the Company’s website approximately two hours after the event.

https://finance.yahoo.com/news/clene-reports-topline-results-demonstrating-120000314.html